Carbapenem Drug Class Shows an Increase in Hospital Inpatient Courses in Europe
Posted on: Thursday, 6 November 2008, 11:17 CST
MALVERN, Pa., Nov. 6 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that in the January -- June 2008 time period, the carbapenem drug class in hospital inpatient courses in Europe has grown seven percent compared to the January -- June 2007 time period. These antibiotics are commonly used to treat lower respiratory infections, systemic infections, abdominal/pelvic infections and GI/biliary infections.
"Among carbapenem antibiotics Merck's Primaxin/Tienam (imipenem/cilastatin) has the largest share of courses (54 percent), followed by AstraZeneca's Merrem/Meronem (meropenem) (36 percent) and Merck's Invanz (ertapenem injectable) (10 percent)," stated Joyce Wedemeyer, product director at AMR. "These shares are consistent with our prior audit for the January -- June 2007 time period."
The newly released European edition of The Hospital Antibiotic Market Guide also finds that just over one-third of all carbapenem courses are used as documented/confirmed therapy. Inpatients treated with a carbapenem course in a documented/confirmed case are most commonly associated with escherichia coli (29 percent of documented courses), pseudomonas aeruginosa (20 percent), methicillin-sensitive staphylococcus aureus (9 percent) and enterococcus faecalis (8 percent).
Why Pharmaceutical Companies Need this Information
The Hospital Antibiotic Market Guide enables pharmaceutical companies to monitor patient shares, costs, infectious disease prevalence and the clinical use of antibiotics in acute care hospitals. In addition, pathogen-level details are available for those inpatient antibiotic drug courses associated with positive microbiological culture results.
About The Hospital Antibiotic Market Guide
The Hospital Antibiotic Market Guide is the industry's most comprehensive audit of inpatient antibiotic usage covering acute care hospitals in the United States, Italy, Germany, France, U.K. and Spain. The information in the audit is abstracted directly from hospital source documents from a panel of demographically representative acute care hospitals of all sizes, including transplant centers. The U.S. data is published twice a year and the European data is published once a year.
About AMR
AMR (http://www.amr-data.com/) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 nmorales@dresources.com emarshall@dresources.com
Arlington Medical Resources
CONTACT: Natalia Morales, +1-781-296-2691, nmorales@dresources.com, orElizabeth Marshall, +1-781-296-2563, emarshall@dresources.com, both forArlington Medical Resources
Web site: http://www.amr-data.com/http://www.decisionresourcesinc.com/
Source: PRNewswire
Related Articles
- Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians' Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
- 50 Largest Wired Telecommunications Carriers in the US Hold 90 Percent of the Market
- JupiterResearch Finds That 48 Percent of Brand Marketers Plan to Use Social Tactics in the Near Term
- Although Large Companies May Build More Than 20,000 Homes Per Year, the Top Ten Builders Together Hold Only 10 to 15 Percent of the Market
- The Outpatient Surgical Center Industry in the US is Highly Fragmented With the 50 Largest Operators Holding Only About 30 Percent of the Market
- Learn What the Current Leading Players in the Hospital Antibiotics Market Are Doing Through Detailed Analyses of Their HA Pipelines
- Numerous Opportunities Exist in the Current Hospital Antibiotics Market As Many Large Pharmaceutical Companies Divest From Antibiotics Drug Development
- The US Plastics and Rubber Products Manufacturing Industry is a Highly Fragmented One With No Manufacturer Holding More Than 2 Percent of the Market
- New-Market Hospitals Reshape Healthcare Delivery to Attract Discriminating Consumers; New Upscale Communities Are a Prime Target for Health System Expansions
- Dramatic Hospital Construction in Denver's Competitive Healthcare Market Results in 1,400 New Inpatient Beds
 |
 |
User Comments (0)
RSS Feeds